A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Single (Outcomes Assessor); Primary Purpose: Treatment
Condition:	Cataracts
Interventions:	Drug: Ketorolac Tromethamine; Drug: Bromfenac; Drug: nepafenac

  Participant Flow

  Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Xibrom	Xibrom to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
Nevanac	Nevanac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
Acuvail	Acuvail to be given preoperatively. One drop BID, 1 day pre op and day of surgery 3 doses prior to surgery.

Participant Flow:   Overall Study

	Xibrom	Nevanac	Acuvail
STARTED	42	42	42
COMPLETED	41	38	42
NOT COMPLETED	1	4	0

  Baseline Characteristics

  Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Xibrom	Xibrom to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
Nevanac	Nevanac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
Acuvail	Acuvail to be given preoperatively. One drop BID, 1 day pre op and day of surgery 3 doses prior to surgery.
Total	Total of all reporting groups

Baseline Measures

	Xibrom	Nevanac	Acuvail	Total
Overall Participants Analyzed; [Units: Participants]	42	42	42	126
Age; [Units: Participants]
<=18 years	0	0	0	0
Between 18 and 65 years	18	15	21	54
>=65 years	24	27	21	72
Age; [Units: Years]; Mean (Standard Deviation)	72 (31)	74 (29)	75 (30)	74 (29)
Gender; [Units: Participants]
Female	26	29	26	81
Male	16	13	16	45
Region of Enrollment; [Units: Participants]
United States	42	42	42	126

  Outcome Measures

1. Primary:

Aqueous PGE2 Inhibition [ Time Frame: Day 4 of treatment ]

  Show Outcome Measure 1

  Serious Adverse Events

  Show Serious Adverse Events

  Other Adverse Events

  Show Other Adverse Events

  Limitations and Caveats

  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

  Hide More Information

Certain Agreements:  

All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  

Name/Title: Frank A. Bucci, Jr., MD
Organization: Bucci Laser Vision
phone: 570-825-5949
e-mail: Buccivision@aol.com

Responsible Party:	Frank A. Bucci, Jr., M.D., Bucci Laser Vision Institute
ClinicalTrials.gov Identifier:	NCT01021761 History of Changes
Other Study ID Numbers:	2009 0199
First Submitted:	November 25, 2009
First Posted:	November 30, 2009
Results First Submitted:	May 25, 2011
Results First Posted:	August 26, 2011
Last Update Posted:	August 31, 2011